oncolytics biotech inc (ONCY) Key Developments
Oncolytics Biotech Inc. Announces Series of Oral and Poster Presentations at 9th International Conference in Boston Ma
Jun 15 15
Oncolytics Biotech Inc. announced that a series of oral and poster presentations are being made by the company's research collaborators at the 9th International Conference on Oncolytic Virus Therapeutics being held from June 13th to 16th, 2015 in Boston MA. Dr. Richard Vile is making an oral presentation regarding previously disclosed findings around augmenting tumor-specific natural killer (NK) responses and specifically attenuating tumor-specific immunosuppression. These data also suggest that the combination of PD-1 inhibition therapy with reovirus oncolytic/immunotherapy represents a readily translatable method to enhance the therapeutic efficacy. The first abstract/poster titled "Targeting peripheral and lymph node resistant CLL with combination reovirus therapy," was authored by Melcher, et al. The authors studied chronic lymphocytic leukemia ("CLL") and the problems associated with eradicating minimal residual disease and drug resistance. They concluded that the combination of reovirus and ABT-263 could increase direct and immune-mediated killing of peripheral disease and that reovirus in combination with Fludarabine may be useful in targeting drug-resistant lymph node disease. The second abstract/poster titled "Oncolysis by reovirus as an immune priming mechanism with VSV-cDNA immunological boosting treats large established tumors," was authored by Melcher, et al. The authors looked at the treatment of established B16 melanoma tumors in a mouse model. They concluded that the local killing of cancer cells by one virus primed the immune system and, by using tumor antigens expressed from a second virus, it was possible to generate potent immunological responses that led to the rejection of well established tumors. The third abstract/poster titled "Monocyte carriage and delivery of reovirus-antibody complexes for melanoma oncolysis," was authored by Melcher, et al. The authors studied preexisting antiviral immunity and found evidence that there is an alternative mechanism by which systemically administered reovirus may gain access to tumors, even in the presence of neutralizing antibodies.
Oncolytics Biotech Inc. - Shareholder/Analyst Call
Jun 5 15
To discuss recent progress in the development of REOLYSIN as a potential cancer therapeutic
Oncolytics Biotech Inc. Announces Phase 1 Study in Pediatric Patients with Brain Tumors
May 19 15
Oncolytics Biotech Inc. announced that submission to the U.S. Food and Drug Administration for review, the Investigational New Drug Application containing the protocol titled MC1472: Phase 1 Study of Replication Competent Reovirus (REOLYSIN) in Combination with GM-CSF in Pediatric Patients with Relapsed or Refractory Brain Tumors is now active. The study is an open-label Phase I trial to clarify the safety, and determine possible efficacy, of GM-CSF given prior to administration of intravenous REOLYSIN for children with malignant high grade brain tumors. GM-CSF will be administered on days one and two of each cycle with REOLYSIN administered on days three, four and five. Cycles will be given every 28 days for up to 12 cycles if patients remain without evidence of tumor progression and without intolerable toxicity. The primary outcome for the nine to 18 patients of the Phase 1 study will be safety and tolerability. Secondary goals include median progression free and overall survival in this patient population.
Oncolytics Biotech Inc. Announces Unaudited Consolidated Earnings Results for First Quarter Ended March 31, 2015
May 7 15
Oncolytics Biotech Inc. announced unaudited consolidated earnings results for first quarter ended March 31, 2015. For the quarter, the company reported operating loss of $3,608,273, loss before loss taxes of $3,551,838, net loss of $3,551,838, net comprehensive loss of $3,326,247 or $0.04 basic and diluted per share, cash used in operating activities of $2,747,189, acquisition of property and equipment of $11,940 compared to the operating loss of $5,569,588, loss before loss taxes of $5,481,601, net loss of $5,485,451, net comprehensive loss of $5,504,145 or $0.06 basic and diluted per share, cash used in operating activities of $6,164,078, acquisition of property and equipment of $15,980 for the same quarter a year ago.
Oncolytics Biotech Inc. Presents at 5th LD Micro Invitational Conference, Jun-02-2015 10:30 AM
May 7 15
Oncolytics Biotech Inc. Presents at 5th LD Micro Invitational Conference, Jun-02-2015 10:30 AM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049, United States. Speakers: Bradley G. Thompson, Executive Chairman, Chief Executive Officer and President.